Delcath Systems tests whether HEPZATO KIT can move beyond metastatic uveal melanoma
Delcath has a liver-response signal in breast cancer. The harder test is whether HEPZATO KIT can prove value beyond a small cohort.
Pharma & Biotech
Pharma & Biotech
What to watch as IDEAYA Biosciences reports OptimUM-02 topline results in uveal melanoma
IDEAYA Biosciences will report OptimUM-02 topline data on April 13. Read why this uveal melanoma trial could shift the treatment landscape.
Pharma & Biotech
ESMO-EURACAN adds CHEMOSAT to uveal melanoma guidance as Delcath Systems strengthens clinical position
Delcath Systems won ESMO-EURACAN guideline recognition for CHEMOSAT in uveal melanoma. Read what this could change for liver-directed cancer care.
Pharma & Biotech
Could IDEAYA Biosciences challenge current standards in metastatic uveal melanoma with darovasertib?
IDEAYA Biosciences nears darovasertib trial data. Discover how results could reshape metastatic uveal melanoma treatment strategies.
Pharma & Biotech
Could five-year survival data position KIMMTRAK as a durable standard in uveal melanoma care
Discover how Immunocore’s five-year KIMMTRAK data could reshape survival expectations in metastatic uveal melanoma. Read the full analysis.
Pharma & Biotech
Delcath subgroup data links survival to tumor burden and LDH in uveal melanoma
New Phase 3 subgroup data suggest Delcath’s HEPZATO KIT improves survival in patients with lower tumor burden or LDH. Learn what this means for mUM treatment.
Medical Devices & Diagnostics
Can Delcath’s HEPZATO redefine the treatment window for metastatic uveal melanoma?
New subgroup data on HEPZATO highlights improved survival in low-burden metastatic uveal melanoma. Find out what this changes in clinical strategy.
Pharma & Biotech
Can IDEAYA’s darovasertib finally redefine first-line therapy in metastatic uveal melanoma?
IDEAYA Biosciences has completed targeted full enrollment in its Phase 2/3 OptimUM-02 trial evaluating darovasertib in combination with crizotinib as a first-line treatment for HLA*A2-negative metastatic uveal melanoma. The company aims to support a potential accelerated approval filing in the United States based on median progression-free survival data expected in the first quarter of 2026.